Showing results (601-610 of 1,892) with videos related to
Sort By:
Pageof 190
Immunotherapy|June 4, 2019
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysisAntonio Rossi, Vincenzo Di Noia, Anastasios Gkountakos, et al.Immunotherapy|February 21, 2022
Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world studyHaoran Zhang, Junru Chen, Xingming Zhang, et al.Immunotherapy|September 4, 2018
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysisAhmad Tarhini, Agnes Benedict, David McDermott, et al.Immunotherapy|September 7, 2018
The potential immune-eliciting cancer testis antigens in colorectal cancerJoanne Ern Chi Soh, Nadiah Abu, Rahman JamalImmunotherapy|October 10, 2018
Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's diseaseJesús Castro-Poceiro, Agnès Fernández-Clotet, Julián PanésImmunotherapy|March 9, 2022
First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusionsPanpan Jiang, Luying Geng, Ziyang Mao, et al.Immunotherapy|March 9, 2022
The effect of low-dose chemotherapy on the tumor microenvironment and its antitumor activity combined with anti-PD-1 antibodyFangyu Lin, Hao Chen, Tao Jiang, et al.Immunotherapy|March 2, 2022
Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinomaLinnea Swanson, Ihab Kassab, Irene Tsung, et al.Immunotherapy|March 2, 2022
Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic reviewAntoine Salloum, Maya Habre, Joanna Abi Chebl, et al.Immunotherapy|August 15, 2018
Subcutaneous belimumab in the treatment of systemic lupus erythematosusOfir Elalouf, Stephanie O Keeling, Zahi ToumaPageof 190